December 16, 2024

Background

Cristina Adriana Popa

This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond

December 2, 2024

Background

swapnil hiremath

BPROAD: Sprinting down the BP Road in Diabetes

This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.

November 30, 2024

news, Meta

joel topf

#HCWvsHunger 2024

Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.

November 18, 2024

Background

Brian Rifkin

Potassium Rollercoaster Heartbreak

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.

November 4, 2024

Background

Jade Teakell

FLOZINATing to the Future- Long Term Effects of ...

This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?

Sparsentan

swapnil hiremath

November 28, 2023

Background

Optimizing “Sparse” Treatments for FSGS

swapnil hiremath

November 28, 2023

Background

This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?

Divya Bajpai

November 27, 2023

The Duplex Study - Visual Abstract

Divya Bajpai

November 27, 2023

Checkout the role of Sparsentan in FSGS - The Duplex Trial VA by NSMC Intern Pallavi Prasad

Divya Bajpai

May 23, 2023

Visual Abstract

PROTECT study on Sparsentan in IgAN - Visual Abstract

Divya Bajpai

May 23, 2023

Visual Abstract

Is Sparsentan effective and safe for patients with IgAN on maximal Raas blockade? Check out the VA by NSMC intern Saumya Vishnoi